1,2-distearoylphosphatidylethanolamine has been researched along with sirolimus in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andes, D; Knilans, K; Kwon, GS; Vakil, R | 1 |
| Dong, Y; Duan, Y; Fu, H; Li, D; Li, Z; Luo, X; Shen, M; Sun, Y; Wang, L; Wu, Z; Xu, C | 1 |
2 other study(ies) available for 1,2-distearoylphosphatidylethanolamine and sirolimus
| Article | Year |
|---|---|
Combination antifungal therapy involving amphotericin B, rapamycin and 5-fluorocytosine using PEG-phospholipid micelles.
Topics: Amphotericin B; Antifungal Agents; Candida albicans; Chemistry, Pharmaceutical; Drug Carriers; Drug Combinations; Drug Stability; Drug Synergism; Flucytosine; Micelles; Microbial Sensitivity Tests; Phosphatidylethanolamines; Polyethylene Glycols; Sirolimus; Solubility; Technology, Pharmaceutical | 2008 |
Efficient Treatment of Atherosclerosis by Dexamethasone Acetate and Rapamycin Co-Loaded mPEG-DSPE Calcium Phosphate Nanoparticles.
Topics: Animals; Atherosclerosis; Autophagy; Calcium Phosphates; Dexamethasone; Endothelial Cells; Lipoproteins, LDL; Mice; Nanoparticles; Phosphatidylethanolamines; Sirolimus | 2020 |